OverviewSuggest Edit

Spero Therapeutics is a biopharmaceutical company developing a pipeline of novel treatments for bacterial infections. The Company’s pipeline of anti-infective agents is one of the most unique in the industry. Spero is pioneering an entirely new therapeutic platform called the Potentiator; this approach has yielded multiple molecules that enhance the utility and potency of many classes of existing drugs to include Gram-negative pathogens. Spero’s DHFR program is exploring the expansion of a novel antifolate’s antibacterial spectrum to treat trimethoprim resistance isolates including Gram-negative pathogens.
TypePublic
Founded2013
HQCambridge, US
Websitesperotherapeutics.com
Employee Ratings4.9

Latest Updates

Employees (est.) (Dec 2019)57(+40%)
Revenue (FY, 2019)$18.1 M(+358%)
Share Price (Nov 2020)$14.7
Cybersecurity ratingAMore

Key People/Management at Spero Therapeutics

Ankit Mahadevia

Ankit Mahadevia

President and CEO
Milind Deshpande

Milind Deshpande

Chairman of the Board
Thomas Parr

Thomas Parr

Chief Scientific Officer
Cristina Larkin

Cristina Larkin

Chief Operating Officer
David Melnick

David Melnick

Chief Medical Officer
Stephen J. Dipalma

Stephen J. Dipalma

Chief Financial Officer (Interim)
Show more

Spero Therapeutics Office Locations

Spero Therapeutics has an office in Cambridge
Cambridge, US (HQ)
675 Massachusetts Ave
Show all (1)

Spero Therapeutics Financials and Metrics

Spero Therapeutics Revenue

Spero Therapeutics's revenue was reported to be $18.15 m in FY, 2019
USD

Revenue (Q3, 2020)

4.0m

Net income (Q3, 2020)

(18.9m)

EBIT (Q3, 2020)

(19.0m)

Market capitalization (17-Nov-2020)

400.6m

Closing stock price (17-Nov-2020)

14.7

Cash (30-Sept-2020)

125.2m

EV

283.6m
Spero Therapeutics's current market capitalization is $400.6 m.
Annual
USDFY, 2017FY, 2018FY, 2019

Revenue

4.0m18.1m

General and administrative expense

10.8m12.9m15.6m

R&D expense

32.9m33.9m65.8m

Operating expense total

43.7m46.8m81.4m
Quarterly
USDQ3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Revenue

463.0k658.0k7.7m2.2m4.6m1.7m1.7m4.0m

General and administrative expense

3.7m3.0m3.1m3.1m3.9m3.8m4.1m4.1m4.5m5.3m

R&D expense

6.9m8.9m7.4m8.5m9.5m12.0m18.5m20.4m15.7m17.7m

Operating expense total

10.6m12.0m10.4m11.6m13.4m15.8m22.6m24.5m20.2m23.0m
Annual
USDFY, 2017FY, 2018FY, 2019

Cash

87.3m34.1m29.7m

Accounts Receivable

1.0m376.0k7.8m

Prepaid Expenses

1.8m7.5m4.8m

Current Assets

92.1m124.2m95.4m
Quarterly
USDQ3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Cash

25.4m52.6m48.7m40.5m49.4m71.1m45.6m64.4m65.3m125.2m

Accounts Receivable

537.0k1.2m794.0k332.0k456.0k2.1m5.0m2.7m4.0m7.1m

Prepaid Expenses

1.0m1.2m1.2m1.2m7.9m6.3m3.7m5.7m9.2m7.3m

Current Assets

27.0m79.7m70.5m133.7m115.7m112.7m104.0m98.0m85.3m142.7m
Annual
USDFY, 2017FY, 2018FY, 2019

Net Income

(39.9m)(41.7m)(60.9m)

Depreciation and Amortization

363.0k409.0k750.0k

Accounts Payable

2.3m84.0k564.0k

Cash From Operating Activities

(39.1m)(39.6m)(50.0m)
Quarterly
USDQ3, 2017

Financial Leverage

-0.4 x
Show all financial metrics

Spero Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

A

99/100

SecurityScorecard logo

Spero Therapeutics Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

CSRHub logo

Spero Therapeutics Online and Social Media Presence

Embed Graph

Spero Therapeutics News and Updates

Spero Therapeutics to Present Data for All Pipeline Programs at IDWeek 2020

15 data presentations cover each of Spero’s three pipeline programs and include a late breaker oral presentation on the Phase 3 ADAPT-PO clinical trial 15 data presentations cover each of Spero’s three pipeline programs and include a late breaker oral presentation on the Phase 3 ADAPT-PO clinical tr…

Spero Therapeutics Hosting Key Opinion Leader Call on Oral Tebipenem HBr for the Treatment of Complicated Urinary Tract Infections

CAMBRIDGE, Mass., Sept. 24, 2020 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and ra…

Spero Therapeutics Announces Pricing of Securities Offering

CAMBRIDGE, Mass., Sept. 11, 2020 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multidrug-resistant (MDR) bacterial infections a…

Spero Therapeutics Announces Positive Topline Results from its Phase 3 ADAPT-PO Clinical Trial of Oral Tebipenem HBr in Complicated Urinary Tract Infection and Acute Pyelonephritis

Pivotal Phase 3 clinical trial of oral tebipenem HBr met primary endpoint, demonstrating statistical non-inferiority versus intravenous ertapenem in patients with complicated urinary tract infection and acute pyelonephritis

Spero Investor Alert: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Spero Therapeutics, Inc. To Contact The Firm

NEW YORK, NY - (NewMediaWire) - June 17, 2020 - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Spero Therapeutics, Inc. ("Spero" or the "Company")(NASDAQ:SPRO).If you invested in Spero stock and would like to discuss your legal rights…

Spero Therapeutics Announces Fourth Quarter and Full-Year 2019 Operating Results and Provides Pipeline Update

2020 catalysts include tebipenem HBr pivotal Phase 3 top-line cUTI data in 3Q20 and SPR720 Phase 2a NTM trial initiation in 2H20 2020 catalysts include tebipenem HBr pivotal Phase 3 top-line cUTI data in 3Q20 and SPR720 Phase 2a NTM trial initiation in 2H20
Show more

Spero Therapeutics Blogs

Spero Therapeutics Announces Third Quarter 2020 Operating Results and Provides Business Update

Achieved key clinical milestones with positive ADAPT-PO Phase 3 data and SPR720 IND acceptance Conference call and live webcast at 4:30 p.m. EST  today CAMBRIDGE, Mass. , Nov. 05, 2020 (GLOBE NEWSWIRE) -- Spero Therapeutics , Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical

Spero Therapeutics to Provide Business Update and Report Third Quarter 2020 Financial Results on Thursday, November 5, 2020

CAMBRIDGE, Mass. , Oct. 29, 2020 (GLOBE NEWSWIRE) -- Spero Therapeutics , Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and

Spero Therapeutics to Present at Investor Conferences in September

CAMBRIDGE, Mass. , Sept. 15, 2020 (GLOBE NEWSWIRE) -- Spero Therapeutics , Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and

Spero Therapeutics Announces Proposed Public Offering

Spero Therapeutics Announces Proposed Public Offering Content Import Wed, 09/09/2020 - 16:33 Spero Therapeutics Announces Proposed Public Offering September 09, 2020 This release is a backfill from a News Wire General CAMBRIDGE, Mass., Sept. 09, 2…

Spero Therapeutics Announces FDA Acceptance of IND Application for SPR720

CAMBRIDGE, Mass. , Aug. 31, 2020 (GLOBE NEWSWIRE) -- Spero Therapeutics , Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant (MDR) bacterial infections,

Spero Therapeutics Announces Second Quarter 2020 Operating Results and Provides Business Update

Spero Therapeutics Announces Second Quarter 2020 Operating Results and Provides Business Update Content Import Thu, 08/06/2020 - 16:08 Spero Therapeutics Announces Second Quarter 2020 Operating Results and Provides Business Update August 06, 2020 This release is a backfill …
Show more

Spero Therapeutics Frequently Asked Questions

  • When was Spero Therapeutics founded?

    Spero Therapeutics was founded in 2013.

  • Who are Spero Therapeutics key executives?

    Spero Therapeutics's key executives are Ankit Mahadevia, Milind Deshpande and Thomas Parr.

  • How many employees does Spero Therapeutics have?

    Spero Therapeutics has 57 employees.

  • What is Spero Therapeutics revenue?

    Latest Spero Therapeutics annual revenue is $18.1 m.

  • What is Spero Therapeutics revenue per employee?

    Latest Spero Therapeutics revenue per employee is $318.4 k.

  • Who are Spero Therapeutics competitors?

    Competitors of Spero Therapeutics include ShiraTronics, UroMems and MicrofluidX.

  • Where is Spero Therapeutics headquarters?

    Spero Therapeutics headquarters is located at 675 Massachusetts Ave, Cambridge.

  • Where are Spero Therapeutics offices?

    Spero Therapeutics has an office in Cambridge.

  • How many offices does Spero Therapeutics have?

    Spero Therapeutics has 1 office.